Fulvestrant Formulation Using DMSO and Triglycerides to Reduce Injection Pain
Solution Overview
Problem
Current fulvestrant injection formulations, particularly FASLODEX, are painful due to the use of castor oil, causing skin irritation, allergic reactions, and gastrointestinal disturbances, and lack long-term stability, necessitating a formulation without castor oil and improved stability.
Innovation Solution
Fulvestrant compositions incorporating dimethyl sulfoxide (DMSO), glycofurol, caprylic and capric triglycerides, and benzyl benzoate or benzyl alcohol, with a solvent: oil mixture: sustained release member volume ratio of 1-2.5:0.9-2.5:0.9-2.5, providing concentrations from 50 mg/ml to 150 mg/ml and achieving long-term stability with reduced impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If castor oil is used as a formulation vehicle, then fulvestrant can be delivered effectively, but the injection becomes extremely painful and causes skin irritation, allergic reactions, and gastrointestinal disturbances
Solution Approach 1:
The patent removes castor oil from the formulation entirely and replaces it with a novel vehicle system comprising dimethyl sulfoxide (DMSO) as the primary solvent, combined with specific oils (medium-chain triglycerides, castor oil-free alternatives) and sustained release agents. This extraction of the harmful substance while maintaining therapeutic efficacy through alternative vehicles directly resolves the contradiction between effective drug delivery and avoidance of painful side effects
Solution Approach 2:
The patent changes the chemical and physical parameters of the formulation vehicle from castor oil-based to a multi-component system with DMSO (20-60% v/v), specific oils (30-60% v/v), and sustained release agents (10-40% w/v). This parameter change in composition fundamentally alters the injection characteristics, reducing pain and irritation while maintaining fulvestrant solubility and delivery efficacy
2Stability of the object's composition
If castor oil derivatives are included in the formulation, then drug stability may be maintained, but long-term stability is insufficient and impurities increase over time
Solution Approach 1:
The patent employs a composite formulation system combining DMSO (solvent), specific oils (stability enhancers), and sustained release agents (release control). This composite material approach creates synergistic effects that simultaneously provide short-term stability during storage and long-term stability over 24+ months, while the sustained release agents control drug release kinetics to prevent impurity formation over time
Solution Approach 2:
The sustained release agents in the formulation act as intermediaries between the fulvestrant drug and the biological system, controlling the release rate and preventing premature degradation. These intermediaries (sustained release agents) mediate the drug's stability profile, ensuring both short-term and long-term stability while minimizing impurity generation during storage and administration
3Ease of manufacture
If castor oil is used as the base, then the formulation can be prepared simply, but the injection volume must be large and pain is increased
Solution Approach 1:
The patent changes the concentration parameter of fulvestrant in the formulation from typical levels to highly concentrated formulations (50-150 mg/ml). This parameter change in concentration allows for significantly reduced injection volumes (e.g., 0.5-2 ml instead of larger volumes) while maintaining or enhancing therapeutic efficacy. The novel vehicle system enables achieving these high concentrations without the pain and irritation associated with castor oil
Solution Approach 2:
By removing castor oil from the formulation, the patent eliminates the substance that causes pain and necessitates larger volumes for effective delivery. The alternative vehicle system achieves better solubility and delivery efficiency, allowing concentrated formulations in smaller, less painful volumes while maintaining ease of manufacture through straightforward preparation procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations are substantially free of castor oil derivatives, exhibit improved long-term stability with less than 5% total impurities after 24 months, and achieve steady-state concentrations for extended periods, reducing pain and improving administration efficacy.
Implementation Method 1
a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof
Implementation Method 2
an oil mixture selected from i) caprylic and capric triglycerides; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid and benzyl alcohol
Data Source
Figure 1
Figure 2
AI summary
Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response ("PAR") basis as determined by high performance liquid chromatography ("HPLC") at a wavelength of 223nm, after at least about 24 months of storage at a temperature of from about 5 °C to about 25 °C.
